Romina Fakhraei

Romina Fakhraei

Auto-generated profile, based on publicly available information

Romina Fakhraei

University of Ottawa, Canada

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2020 in Obesity Reviews
Verified
Journal Article
Open access
PDF file
ASAlexandre Simon
Alexandre Simon
MPMisty Pratt
Misty Pratt
BHBrian Hutton
Brian Hutton
BSBecky Skidmore
Becky Skidmore
RFRomina Fakhraei
Romina Fakhraei
LGLaura M. Gaudet
Laura M. Gaudet
Summary: Multiple clinical practice guidelines (CPGs) have been established for pregnant women with obesity. The quality and consistency of recommendations remain unknown. The objective of this study is to conduct a systematic review to synthesize and appraise evidence from CPGs, available worldwide, for pregnant women affected by obesity. An experienced information specialist performed a rigorous search of the literature, searching MEDLINE, Embase, grey literature, and guideline registries to locate CPGs that reported on pregnancy care relating to obesity. CPGs related to antenatal care of pregnant women with obesity (pre‐pregnancy body mass index [BMI] ≥ 30 kg/m2) in low‐risk (eg, care provider = family physician or midwife) or high‐risk settings (eg, obstetrician or maternal fetal medicine) were included. CPGs were appraised for quality with independent data collection by two raters. Information was categorized into five domains: preconception care. care during pregnancy, diet and exercise during pregnancy, care immediately before, during, and after delivery, and postpartum care. The literature search yielded 2614 unique citations. Following screening of abstracts and full texts, 32 CPGs were included, with quality ranging between 0 and 100 on the AGREE II tool. The strongest evidence related to nutritional advice, exercise, and pregnancy risk counselling. Guidance was limited for timing of screening tests, antenatal visits and delivery, ideal postpartum care, and management of adverse pregnancy outcomes. Most guidelines in this population are not evidence based. Research is needed to bridge knowledge gaps pertaining to fetal antenatal surveillance, management of adverse outcomes and postpartum care, and enhance consistency across CPGs.

16 August 2021 in Paediatric and Perinatal Epidemiology
Verified
Journal Article
Open access
PDF file
SSSebastian Srugo
Sebastian Srugo
DFDeshayne B. Fell
Deshayne B. Fell
DCDaniel J Corsi
Daniel J Corsi
RFRomina Fakhraei
Romina Fakhraei
YGYanfang Guo
Yanfang Guo
LGLaura Gaudet
Laura Gaudet
Background: Studies suggest maternal weight and weight gain during pregnancy may influence foetal immunological development. However, their role in the aetiology of allergic disease is unclear.Objectives: We sought to examine the impact of maternal pre‐pregnancy body mass index (BMI) and gestational weight gain (GWG) on the incidence of four common paediatric allergic diseases.Methods: We conducted a retrospective, population‐based cohort study of all singleton live births in Ontario, Canada between 2012 and 2014, using maternal‐newborn records from the provincial birth registry linked with health administrative databases. Neonates were followed up to 7 years for anaphylaxis, asthma, dermatitis and rhinitis, identified through validated algorithms based on healthcare encounters. We multiply imputed missing data and employed Cox proportional‐hazards models to calculate adjusted hazard ratios (aHR) with 95% confidence intervals (CI). To test the robustness of our findings, we also conducted several sensitivity analyses, including probabilistic bias analyses for exposure and outcome misclassification. All methods were prespecified in a published protocol.Results: Of the 248,017 infants followed, 52% were born to mothers with a pre‐pregnancy BMI in the normal range and only 19% were born to mothers with adequate weight gain during pregnancy. Incidence rates (per 100,000 person‐days) for anaphylaxis, asthma, dermatitis and rhinitis were 0.22, 6.80, 12.41 and 1.54, respectively. Compared with normal BMI, maternal obesity was associated with increased hazards of asthma in offspring (aHR 1.08, 95% CI 1.05, 1.11), but decreased hazards of anaphylaxis (aHR 0.83, 95% CI 0.69, 0.99) and dermatitis (aHR 0.97, 95% CI 0.94, 0.99). In contrast, maternal underweight was associated with increased hazards of dermatitis (aHR 1.06, 95% CI 1.02, 1.10). We found no associations between pre‐pregnancy BMI and rhinitis or GWG and any allergic outcome, and no evidence of effect measures modification by infant sex.Conclusions: These findings provide support for the involvement of maternal pre‐pregnancy BMI in paediatric allergic disease development.

24 October 2024 in The Lancet Regional Health - Americas
Verified
Journal Article
Open access
RFRomina Fakhraei
Romina Fakhraei
DFDeshayne B. Fell
Deshayne B. Fell
DEDarine El-Chaâr
Darine El-Chaâr
NTNisha Thampi
Nisha Thampi
BSBeate Sander
Beate Sander
KWKumanan Wilson
Kumanan Wilson
Background Group B Streptococcus (GBS) significantly contributes to neonatal sepsis and meningitis, with varying disease rates reported globally and limited population-based data. We estimated infant GBS disease burden in Ontario, Canada and assessed the association of maternal GBS screening (35-37 weeks' gestation) and intrapartum antibiotic prophylaxis (IAP) provision with infant disease rates. Methods Our population-based cohort study included pregnant individuals and their offspring from April 2012 to March 2018, utilising the provincial birth registry linked to health administrative data. GBS cases were ascertained through culture results and diagnostic codes. We calculated incidence rates for early-onset disease (EOD: 0-6 days), late-onset disease (LOD: 7-89 days), and ultra-LOD (ULOD: 90-365 days). Adjusted incidence rate ratios (aIRR) were derived via log-binomial regression to compare infant GBS rates according to screening and IAP-receipt. Findings Among 776,148 liveborn infants, we identified 803 with GBS, with multiples exhibiting a threefold incidence increase. Incidence rates of EOD, LOD and ULOD were 0.49, 0.46 and 0.07 per 1000 livebirths, respectively. Of eligible pregnancies, 94% were screened; 23% screened positive, and 81% of them received IAP. Nearly 12% of term EOD infants had mothers who missed IAP despite screening positive. Maternal screening was associated with lower rates of any infant GBS disease (aIRR: 0.60; 95% CI: 0.45, 0.80). Among screen-positive births, IAP-receipt was associated with reduced rates of EOD (aIRR: 0.72, 95% CI: 0.48, 1.29) and LOD/ULOD (aIRR: 0.69; 95% CI: 0.46, 1.05), but confidence intervals included 1.0. Interpretation Our study, the largest Canadian investigation into infant GBS disease, highlights both widespread adoption and ongoing challenges of the current prevention strategy. Funding Canadian Institutes of Health Research. Copyright (c) 2024 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).

2 July 2025 in The Lancet Regional Health - Americas
Verified
Journal Article
Open access
RFRomina Fakhraei
Romina Fakhraei
DFDeshayne B. Fell
Deshayne B. Fell
DEDarine El-Chaâr
Darine El-Chaâr
NTNisha Thampi
Nisha Thampi
BSBeate H Sander
Beate H Sander
KWKumanan Wilson
Kumanan Wilson
Group B Streptococcus (GBS) is a leading infectious cause of neonatal morbidity and mortality worldwide, yet data on longer-term outcomes in children remain limited. We aimed to assess the risk of neurodevelopmental impairments (NDIs) in GBS survivors and to explore effect modification by sex and prematurity. We performed a population-based cohort study of liveborn infants in Ontario between April 2012 and March 2018, using linked birth registry, laboratory, and health administrative databases. GBS disease in the first year of life was ascertained through culture results and diagnostic codes. NDIs, encompassing cognitive, motor, sensory (hearing, vision), and social/behavioural domains, were ascertained up to five years of age using diagnostic codes. Cox regression was used to estimate adjusted hazard ratios (aHR) for overall, domain-specific, and multidomain NDIs, comparing children with and without GBS disease during infancy. Of 764,934 infants, 771 had a history of GBS disease. GBS survivors had a twofold increased risk of any NDI (adjusted hazard ratio [aHR]: 2.18 [95% CI: 1.88, 2.54]) and higher rates of cognitive (aHR: 2.79 [95% CI: 2.37, 3.30]), motor (aHR: 7.08 [95% CI: 2.93, 17.08]), social/behavioural (aHR: 1.60 [95% CI: 1.20, 2.14]), and sensory (aHR: 1.64 [95% CI: 1.02, 2.64]) impairments. Male children and those born preterm (<37 weeks) had disproportionately higher risks of GBS-associated NDIs. GBS disease in infancy is associated with a higher risk of NDIs by age five years, particularly for male children and those born preterm. Primary prevention strategies are needed to mitigate long-term developmental impacts of early-life GBS disease. 10.13039/501100000024 Canadian Institutes of Health Research .

10 June 2026 in Gastro Hep Advances
Verified
Journal Article
Open access
YKYestle Kim
Yestle Kim
RFRomina Fakhraei
Romina Fakhraei
JOJohn C. O’DOnnell
John C. O’DOnnell
KJKarissa Johnston
Karissa Johnston
MBMelissa Bather
Melissa Bather
ADAmreen Dinani
Amreen Dinani
Metabolic dysfunction–associated steatohepatitis (MASH) affects approximately 5% of adults globally and, without effective treatment, may progress to end-stage liver disease (ESLD), including compensated cirrhosis, decompensated cirrhosis (DC), hepatocellular carcinoma, and liver transplantation. Using real-world data, this study characterized the natural history and health-care impact of MASH among US adults. A retrospective cohort study was conducted using Optum’s deidentified Market Clarity Data (January 2021–March 2024). Noninvasive test (NIT) use at diagnosis (days 0–30) and during follow-up was described. Predictors of progression were estimated with modified Poisson regression, time to first ESLD was assessed with Cox models, and health-care resource utilization (HCRU) and costs with multivariable regression. Among 49,983 patients with MASH, 16,359 (32.7%) had ESLD at baseline (compensated cirrhosis 3965; DC 11,406; hepatocellular carcinoma 514; liver transplantation 474). Of the 33,624 without baseline ESLD, 15.9% progressed; median time to first ESLD event was 10.6 months (interquartile range: 3.8–19.7), with DC the most frequent first event. Around diagnosis, 3771 patients (7.5%) underwent ≥1 NIT or imaging test, slightly higher with baseline ESLD than without (8.1% vs 7.3%); NIT/imaging use increased during follow-up. Older age, hypertension, type 2 diabetes, cardiovascular disease, sleep apnea, smoking, and thyroid disease were associated with higher progression risk. Patients who progressed had higher HCRU and costs than those who did not progress. In this large US cohort, progression from MASH to ESLD was associated with high HCRU and costs, particularly among patients with ESLD or subsequent progression. These findings highlight the need for earlier risk stratification and targeted care to mitigate burden.